Iovance Biotherapeutics, Inc. IOVA Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s total non-current liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported total non-current liabilities of $74.49M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s total non-current liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total non-current liabilities decreased by 2.2% year-over-year, from $76.18M to $74.49M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total non-current liabilities?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total non-current liabilities has grown at a 6.0% compound annual growth rate (CAGR), from $57.09M to $76.23M.
- What does total non-current liabilities mean?
- The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.